What's Biotech in Hebrew?

Sandler, Neal
December 2007
Red Herring;12/1/2007, Vol. 4 Issue 30, p52
Trade Publication
The article focuses on venture investment in life sciences and biotechnology industry in Israel. The country is getting a reputation in life sciences with medical device companies like Johnson & Johnson, Boston Scientific, Medtronic, GE Medical, Kodak and Phillips spending billions to acquire Israeli companies and technologies. Life sciences now account for 25 percent of all venture capital investments, and this figure is likely to go higher in the coming years, according to Zeev Holtzman, founder and chairman of Giza Venture Partners. Israel has developed top-selling drugs for Teva, Johnson & Johnson and Swiss drug maker Serono Group. Israel has also become a major center for stem cell research.


Related Articles

  • The Rapidly Changing World of Biotech.  // R&D Magazine;Sep2007, Vol. 49 Issue 9, pG8 

    This article explains that while biotechnology was the technology realm of Europe and the U.S. for many years, it has now become a global industry. The maturing of the industry and the competition for resources is accelerating as the number of countries now supporting viable and growing life...

  • Michigan: It Isn't Just for Automakers Anymore. McLeod, Lorna D. // BioPharm International;Jul2002, Vol. 15 Issue 7, p8 

    Reports on the efforts of Michigan to attract high technology business to the area. Tax incentives; Designated high technology areas; Establishment of growth capital fund; Venture capital funding; Life science companies in the area. INSETS: Life Sciences in Michigan;Michigan Life Sciences in...

  • High stakes cause ethical problems. Davidson, D. Kirk // Marketing News;5/22/95, Vol. 29 Issue 11, p8 

    The article presents information on the marketing ethics problem of drug companies Genentech Inc. and Johnson & Johnson. When the biotechnology industry was still in its infancy, Genentech Inc. was the very first company in the world to market a genetically engineered product. It was able to...

  • VC Investments in Biotech Dip 12%, But Deal Size Doubles. Robbins-Roth, Cynthia // BioWorld Today;10/5/2011, Vol. 22 Issue 193, p1 

    The article reports that investments in biotech companies for the first nine months of 2011 dropped 12% from last year. It mentions that despite the fall in venture capital, 72 companies were able to raise 1.5 billion dollars which is still a substantial amount. The investment trends in Series A...

  • Series A And B Rounds Up As Early Stage Model Evolves. Morrison, Trista // BioWorld Today;5/1/2007, Vol. 18 Issue 85, p1 

    The article reports on the flow of venture capital money into and through the biotechnology industry for the first quarter of 2007. According to data from "BioWorld Financial Watch" and BioWorld Snapshots, of the $2.1 billion in venture capital invested in global biotechnology companies,...

  • GSK, J&J Join Index Ventures' Asset-Based $199M VC Fund. Moran, Nuala // BioWorld International;3/28/2012, Vol. 17 Issue 13, p1 

    The article reports that Index Ventures launched a venture capital fund worth 150 million euros with the involvement of GlaxoSmithKline plc and Johnson & Johnson. The fund will be used in investing in first-in-class or best-in-class products which are based on novel science and in meeting the...

  • Glaxo Joins J&J in $200 Million Fund with Index Ventures.  // MondayMorning;3/26/2012, Vol. 20 Issue 13, p1 

    The article states that a 200 million dollar fund will be formed by the companies GlaxoSmithKline Plc and Johnson & Johnson (J&J) with the company Index Ventures in order to make investments in early-stage biotechnology companies. It is mentioned that this move may lure venture capitalists back...

  • BioCrossroads takes next step.  // Indianapolis Business Journal;12/26/2004, Vol. 25 Issue 42, p10 

    Discusses developments indicating the progress of central Indiana's BioCrossroads program. David Johnson's appointment to replace Chuck Schalliol to lead the life sciences effort; Partnership between entrepreneurs Bruce Bodner and Raul Zavaleta to strike the first private deal to develop space...

  • The Technology Behind Best Practices. Branca, Malorye // Bio-IT World;Jul2003, Vol. 2 Issue 7, p70 

    Focuses on the role of information technology in drug discovery and development as revealed in the 2003 Best Practices Awards of "Bio·IT World." List of information technology vendors which contributed to drug development.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics